Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Dna X (SONM) over the last 7 years, with Q3 2025 value amounting to 45.47%.

  • Dna X's Return on Capital Employed rose 463100.0% to 45.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 45.47%, marking a year-over-year increase of 463100.0%. This contributed to the annual value of 8.1% for FY2024, which is 81300.0% down from last year.
  • According to the latest figures from Q3 2025, Dna X's Return on Capital Employed is 45.47%, which was up 463100.0% from 85.86% recorded in Q2 2025.
  • Dna X's 5-year Return on Capital Employed high stood at 45.47% for Q3 2025, and its period low was 85.86% during Q2 2025.
  • In the last 5 years, Dna X's Return on Capital Employed had a median value of 1.14% in 2021 and averaged 6.05%.
  • The largest annual percentage gain for Dna X's Return on Capital Employed in the last 5 years was 463100bps (2025), contrasted with its biggest fall of -853000bps (2025).
  • Dna X's Return on Capital Employed (Quarter) stood at 2.04% in 2021, then skyrocketed by 61bps to 0.8% in 2022, then soared by 103bps to 0.02% in 2023, then crashed by -234965bps to 47.85% in 2024, then soared by 195bps to 45.47% in 2025.
  • Its Return on Capital Employed was 45.47% in Q3 2025, compared to 85.86% in Q2 2025 and 9.56% in Q1 2025.